NICE NG123: Urinary Incontinence and Pelvic Organ Prolapse in Women: Management
Classification of Urinary Incontinence
NG123 divides urinary incontinence into three categories that determine the management pathway: stress urinary incontinence (leakage on effort/exertion), urgency urinary incontinence/overactive bladder, and mixed urinary incontinence (features of both) — in mixed incontinence, treat the predominant/most bothersome symptom first.
Investigation and Assessment
A bladder diary (minimum 3 days, covering usual activities) is recommended as part of initial assessment. Urodynamic testing is not required before primary surgery for stress incontinence when the clinical diagnosis is clear, but should be performed before surgery if there is urge-predominant mixed incontinence, suspected voiding dysfunction, anterior/apical prolapse, or prior continence surgery. Pad testing, Q-tip/Bonney tests, routine cystoscopy, and routine imaging are not recommended for standard assessment.
Management Ladder: Urinary Incontinence
Conservative (first-line): Lifestyle advice (reduce caffeine for overactive bladder, modify fluid intake, weight loss if BMI >30); supervised pelvic floor muscle training for at least 3 months as first-line for stress or mixed incontinence (minimum 8 contractions, 3 times daily, continued if beneficial); bladder training for a minimum of 6 weeks for urgency or mixed incontinence.
Pharmacological (overactive bladder/urgency): Anticholinergics (antimuscarinics) at the lowest acquisition cost, reviewed at 4 weeks and switched if ineffective or poorly tolerated (avoid flavoxate, propantheline, imipramine, and immediate-release oxybutynin in older women); mirabegron/vibegron per relevant NICE technology appraisals; desmopressin for nocturia (caution in patients over 65 with cardiovascular disease); vaginal oestrogen for overactive bladder symptoms associated with menopausal genitourinary syndrome. Duloxetine is not first-line and is reserved as a second-line option only when surgery for stress incontinence is declined or unsuitable.
Invasive management of overactive bladder (after conservative/pharmacological failure, via MDT): Intravesical botulinum toxin A (starting at 100 units, increasing to 200 units if inadequate response, with acceptance of the possible need for clean intermittent self-catheterisation); percutaneous sacral nerve stimulation if botulinum toxin is ineffective or unacceptable; augmentation cystoplasty and urinary diversion reserved for refractory cases willing to accept lifelong follow-up and (for cystoplasty) self-catheterisation.
Surgical management of stress incontinence: Offer a choice between colposuspension (open or laparoscopic), autologous rectus fascial sling, and retropubic mid-urethral mesh sling (type 1 macroporous polypropylene; retropubic route preferred over transobturator). Intramural bulking agents may be considered if other options are unsuitable, with an explicit discussion of limited long-term evidence. Anterior colporrhaphy, needle suspension, paravaginal repair, porcine dermis grafts, and the Marshall–Marchetti–Krantz procedure are not recommended. Post-operative follow-up includes review within 6 months with vaginal examination for mesh exposure.
Pelvic Organ Prolapse: Assessment and Management Ladder
Assessment: Use the POP-Q system to document the degree of prolapse in the anterior, central (apical), and posterior compartments, alongside assessment of pelvic floor muscle activity. Imaging is not routinely required when prolapse is evident on examination.
Conservative (first-line): Lifestyle modification (weight loss if BMI >30, avoiding heavy lifting, preventing constipation); vaginal oestrogen for associated menopausal genitourinary symptoms; supervised pelvic floor muscle training for at least 16 weeks in POP-Q stage 1–2 prolapse; vaginal pessaries offered alone or alongside pelvic floor training, with removal/reinsertion at least every 6 months to reduce complications.
Surgical management (by compartment/site):
- Uterine prolapse: if uterine preservation is not a priority — vaginal hysterectomy (± sacrospinous fixation), vaginal sacrospinous hysteropexy, Manchester repair, or sacrohysteropexy with mesh; if preservation is desired — sacrospinous hysteropexy, Manchester repair (unless future pregnancy is planned), or mesh sacrohysteropexy.
- Vault prolapse: vaginal sacrospinous fixation with sutures, or abdominal/laparoscopic sacrocolpopexy with mesh.
- Anterior compartment: anterior repair without mesh.
- Posterior compartment: posterior repair without mesh.
- Colpocleisis is an option for vault or uterine prolapse in women not wishing to retain the possibility of penetrative intercourse who are at higher surgical risk.
Mesh type and permanence must be documented and recorded on a national mesh registry, with written implant information given to the patient. Post-operative review at 6 months includes vaginal examination for mesh exposure. When stress incontinence coexists with anterior/apical prolapse, concurrent surgery may be considered, but uncertainty about efficacy beyond 1 year and increased complication risk relative to sequential surgery should be discussed with the patient.
High-Yield Exam Points
- NG123 is the current, broad NICE guideline covering assessment and management of both urinary incontinence and pelvic organ prolapse; the older RCOG GTG 35 addresses only the surgical treatment of urodynamic stress incontinence and should be treated as historical/superseded context, not the primary reference.
- Urodynamics are not required before primary stress incontinence surgery with a clear clinical diagnosis — a frequently tested negative recommendation.
- Supervised pelvic floor muscle training is first-line for stress/mixed urinary incontinence (≥3 months) and for POP-Q stage 1–2 prolapse (≥16 weeks) before considering surgery or pessary.
- For stress incontinence surgery, patients are offered a choice of colposuspension, autologous rectus fascial sling, or retropubic mid-urethral mesh sling — procedures such as anterior colporrhaphy and needle suspension are explicitly not recommended.
- Anterior and posterior compartment prolapse repairs should be performed without mesh; mesh is reserved for apical/vault procedures (sacrocolpopexy, sacrohysteropexy) with mandatory registry documentation.
- Duloxetine for stress incontinence is second-line only, used when surgery is declined or unsuitable — not a first-line pharmacological option.
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG) or NICE.
Source: National Institute for Health and Care Excellence (NICE) — current primary source, broader than and superseding the archived RCOG GTG 35 (which covers only the surgical treatment of urodynamic stress incontinence) (24 June 2019 (surveillance review 3 July 2026 confirmed no update needed to the surgical management of stress urinary incontinence recommendations))
Read the original on nice.org.uk
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).